UK’s NICE Backs BMS's Opdivo In Lung Cancer, But Only Via CDF With Price Cut
Executive Summary
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only through the UK's revamped Cancer Drugs Fund, and at a discounted price.